RAS Inhibitors

PreclinicalSmall molecule

AAssistance Publique - Hôpitaux de Paris

RAS Inhibitors is one of 28 small molecule programs targeting Albuminuria. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AlbuminuriaActive, not recruiting

AlbuminuriaPreclinical

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Albuminuria

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Approved

1 2

Kerendia

Bayer

Approved

1 3

Onglyza

AstraZeneca

Approved

1 4

Amaryl

Sanofi

Approved

1 5

Tekturna

Tibotec Pharmaceuticals, Ireland

Approved

2 6

Singulair

OOrganon and Co

Approved

1 7

Januvia

ZZydus Therapeutics Inc.

Approved

1 8

Micardis

Boehringer Ingelheim

Approved

1 9

Jardiance

Boehringer Ingelheim

Approved

1 10

Tradjenta

Boehringer Ingelheim

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Albuminuria1 trial

Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT01195818·53 enrolled

Cardiovascular Events1 trial

The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value

Unknown status·SShenzhen Second People's Hospital·Phase 4·NCT04572724·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for RAS Inhibitors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RAS Inhibitors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RAS Inhibitors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAssistance Publique - Hôpitaux de Paris

RAS Inhibitors

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Albuminuria1 trial

Cardiovascular Events1 trial

References

Drug Info

Quick Facts

Related News